Reports Q3 revenue $3.56B, consensus $3.56B. “Labcorp’s (LH) third-quarter performance reflects continued momentum in our Diagnostics and Central Laboratory businesses, resulting in strong revenue growth and margin improvement,” said Adam Schechter, chairman and CEO of Labcorp. “We advanced our strategy by forming new partnerships with health systems and regional laboratories, introducing innovative tests in key specialty areas and leveraging science and technology to improve customer experience and operational efficiency. Our performance led to double-digit adjusted EPS growth and strong cash flow in the quarter. We expect to finish the year strong as we remain focused on delivering value to our customers and shareholders.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp’s Role in Pioneering Non-Invasive Preeclampsia Screening: A Market Perspective
- Notable companies reporting before tomorrow’s open
- LH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Labcorp to offer Elecsys pTau181 test for Alzheimer’s disease
- Quest Diagnostics price target raised to $207 from $191 at Morgan Stanley